Stockpiling of Meningococcal Vaccine

Dr. Suresh Jadhav
Executive Director
Serum Institute of India Pvt. Ltd., Pune
ssj@seruminstitute.com

DCVMN Supply Chain Workshop 30-31 Mar2021
Current Scenario

- Stockpile requirements of UNICEF since last 5 years has remained constant @ 1.5million doses per year.
- Current contract is valid till 31 Dec’2021
- Current discussion with UNICEF does not figure any stockpile for future supplies for reasons known to them
- Serum Institute of India was maintaining this stockpile and if there is no requirement in future from UNICEF, we will have to take appropriate decision
- The stockpile is to be maintained by the manufacturer for which there is no payment is done by UNICEF
Current Scenario

• It means, the total responsibility of maintaining and carry forward of this stock is with the manufacturer without any financial obligations on procurement agency.

• In other words, if anything happens, the manufacturer is responsible, whereas the procurement agency has no liability to procure the stock from the manufacturer.
2.7 STOCK MANAGEMENT & EMERGENCY DELIVERIES

- Awarded manufacturers will be requested to have a stockpile ready for emergency delivery. The volume of this stock will be defined in any resultant LTA from this tender. The manufacturers will be requested to manage the stock and ensure the emergency response stock level maintains the minimum acceptable shelf life.

- Manufacturers will be requested to make vaccine available for shipment within 48 hours after receipt of an order from UNICEF.
4.4.5 EMERGENCY AND OUTBREAK RESPONSE DELIVERY LEAD TIMES

- For outbreak response, stockpile holders are requested to make vaccine available for shipment 48 hours after receipt of a purchase order.

- Specific quantities and terms will be negotiated with each awarded manufacturer based on the information provided by the manufacturer in their Proposal.
4.4.6 EMERGENCY STOCKPILE STORAGE REQUIREMENT

- The Proposer agrees to store the awarded annual stock of vaccines until requested to release in response to an emergency outbreak or released for other uses.

- The awarded supplier remains the sole proprietor of the vaccines during the storage period.
4.5 SHELF LIFE

- Vaccine shall be supplied with the maximum shelf life possible consistent with current vaccine production technology and stability data. Unless separately authorized by UNICEF, the remaining shelf life at the time of dispatch shall not be less than the figures stated below:

- Meningococcal C- and W-containing (polysaccharide and/or conjugate): 18 months
- Meningococcal A conjugate (10 mcg): 20 months